Yellox (bromfenac) eye drops launched

29 July 2011, 9:30am

Yellox (bromfenac) eye drops are now available for the treatment of ocular inflammation following cataract extraction.

Yellox is administered less often than many other anti-inflammatories, which may aid patient adherence

Bromfenac is an NSAID that exerts its anti-inflammatory effect through inhibition primarily of cyclooxygenase-2, and to a lesser extent cyclooxygenase-1.¹

Efficacy was displayed in 2 phase III, randomised, placebo-controlled, double-blind studies (n=527).¹ In patients who received bromfenac twice daily starting approximately 24 hours after surgery and continuing for up to 14 days, a greater proportion experienced complete clearance of ocular inflammation on day 15 compared with patients who received placebo (64.0% vs 43.3%; p<0.0001). In addition, anterior chamber cell and flare scores within 2 weeks of surgery were lower in the treatment arms than in the placebo groups (flare score ≤1, 85.1% vs 52.0%).

REFERENCES